- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Pharmacyclics agent cleared in U.K.
Pharmacyclics of Sunnyvale, CA, has received regulatory approvalin the U.K. for its Gadolite oral MRI contrast agent, which isindicated for diagnosing pelvic and abdominal disorders. Gadolitewill be marketed in the U.K. and the rest of Europe by E-Z-EMof
Pharmacyclics of Sunnyvale, CA, has received regulatory approvalin the U.K. for its Gadolite oral MRI contrast agent, which isindicated for diagnosing pelvic and abdominal disorders. Gadolitewill be marketed in the U.K. and the rest of Europe by E-Z-EMof Westbury, NY, under a deal between the two companies announcedthis month. E-Z-EM will file marketing applications for Gadolitein additional European countries under the European Union's mutualrecognition process.
E-Z-EM also has rights to Gadolite in the U.S., Canada, andMexico. A new drug application for Gadolite was filed with theFood and Drug Administration in September, according to the companies.Gadolite is manufactured by Glaxo Wellcome.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
